NCT00640978 2025-05-01
Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
Clinical Trials
61 trialsNCT01313559 2025-04-30
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT00253318 2025-04-27
RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT03839940 2025-01-29
MIST
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT00811590 2024-09-19
Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome
University of Utah
Phase 2 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT01345136 2024-02-13
Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
Jonsson Comprehensive Cancer Center
Phase 2 Terminated
NCT01215136 2023-11-24
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT00934895 2023-09-18
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
Rutgers, The State University of New Jersey
Phase 1/2 Terminated
NCT02023905 2022-12-29
Everolimus With and Without Temozolomide in Adult Low Grade Glioma
University of California, San Francisco
Phase 2 Terminated
NCT01582009 2022-08-15
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT02269670 2022-04-05
Phase II Study of Everolimus Beyond Progression
Emory University
Phase 2 Terminated
NCT01499160 2022-02-11
Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
University of Maryland, Baltimore
Phase 2 Terminated
NCT02236572 2022-02-01
Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score
Yale University
Phase 2 Terminated
NCT00972335 2021-11-10
Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT01784861 2021-07-08
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
Washington University School of Medicine
Phase 1/2 Terminated
NCT01185366 2021-04-28
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01125293 2021-04-23
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
Phase 1/2 Terminated
NCT01190241 2020-11-20
TSAP
Amsterdam UMC, location VUmc
Phase NA Terminated
NCT01627067 2020-06-19
Exemestane-RAD001-Metformin
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01133678 2020-05-08
Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck
University of Chicago
Phase 2 Terminated
NCT01111058 2020-04-07
Everolimus Versus Placebo in Head and Neck Cancer
University of Chicago
Phase 2 Terminated
NCT01057277 2020-02-17
RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer
Brown University
Phase 1 Terminated
NCT02254239 2019-12-12
Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Mayo Clinic
Phase 1 Terminated
NCT03578432 2019-12-02
Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy
University of Arizona
Phase EARLY_PHASE1 Terminated
NCT01648465 2019-09-03
Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors
Hellenic Cooperative Oncology Group
Phase 2 Terminated
NCT03014297 2019-08-08
Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression
University of Kentucky
Phase 1 Terminated
NCT00526591 2018-12-06
Everolimus in Treating Patients With Newly Diagnosed Localized Prostate Cancer
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT01009346 2018-07-17
RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Terminated
NCT02338570 2018-02-05
ORCHIDEE
Mario Negri Institute for Pharmacological Research
Phase 4 Terminated
NCT02479490 2018-01-16
PREV
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Terminated
NCT00807755 2018-01-09
Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors
University of California, Davis
Phase 1 Terminated
NCT01051791 2017-12-19
Phase II Study of RAD001 Head and Neck Cancer
University of Pittsburgh
Phase 2 Terminated
NCT01508104 2017-08-23
Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors
University of Cincinnati
Phase 1 Terminated
NCT01642732 2017-05-30
Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 1 Terminated
NCT00651482 2017-04-11
Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)
Stanford University
Phase 2 Terminated
NCT01637090 2017-01-12
CTCL
Boston Medical Center
Phase 2 Terminated
NCT00978432 2016-11-25
Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Duke University
Phase 2 Terminated
NCT00831480 2016-03-21
Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal
Baylor College of Medicine
Phase 2 Terminated
NCT01773460 2016-02-10
Evelyn
GBG Forschungs GmbH
Phase 3 Terminated
NCT01888042 2016-02-10
POORTOR
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated
NCT01042028 2015-10-20
A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer
Odense University Hospital
Phase 1/2 Terminated
NCT01889420 2015-07-31
Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
New Mexico Cancer Research Alliance
Phase 1 Terminated
NCT01009801 2015-07-07
Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer
Swiss Cancer Institute
Phase 1/2 Terminated
NCT00933374 2015-03-18
RAD001
Heinrich-Heine University, Duesseldorf
Phase 2 Terminated
NCT00390364 2014-10-08
Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT01149434 2014-10-06
Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers
University of Utah
Phase 1/2 Terminated
NCT01793636 2014-06-24
ZEBRA
Queen Mary University of London
Phase 2 Terminated
NCT01096199 2014-01-22
A Study of TS-1, Cisplatin (CDDP) and RAD001 (Everolimus)
National University Hospital, Singapore
Phase 1 Terminated